Last reviewed · How we verify
KHK7791
KHK7791 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key coagulation cascade enzyme, thereby reducing thrombotic risk.
KHK7791 is a Factor XIa inhibitor that reduces thrombin generation by blocking a key coagulation cascade enzyme, thereby reducing thrombotic risk. Used for Thrombotic disorders and stroke prevention (Phase 3 development).
At a glance
| Generic name | KHK7791 |
|---|---|
| Also known as | Tenapanor |
| Sponsor | Kyowa Kirin Co., Ltd. |
| Drug class | Factor XIa inhibitor |
| Target | Factor XIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
KHK7791 selectively inhibits Factor XIa, an enzyme in the intrinsic coagulation pathway. By blocking Factor XIa, the drug reduces the amplification of thrombin generation while potentially preserving hemostasis through the extrinsic pathway, offering a mechanism that may provide antithrombotic benefit with reduced bleeding risk compared to conventional anticoagulants.
Approved indications
- Thrombotic disorders and stroke prevention (Phase 3 development)
Common side effects
Key clinical trials
- A Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on HD (PHASE2)
- Dose-finding Study of KHK7791 in Hyperphosphatemia Patients (PHASE2)
- Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients (PHASE2)
- Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis (PHASE3)
- Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis (PHASE3)
- Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis (PHASE3)
- Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KHK7791 CI brief — competitive landscape report
- KHK7791 updates RSS · CI watch RSS
- Kyowa Kirin Co., Ltd. portfolio CI